SCI时时刷

search
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared wi...
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on pr...
How we treat primary immune thrombocytopenia in adults
How we treat primary immune thrombocytopenia in adults
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts a...
Payload diversification: a key step in the development of antibody–drug conjugates
Payload diversification: a key step in the development of antibody–drug conjugates
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selec...
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety
The antiphagocytic molecule CD47 is overexpressed in a wide variety of cancer cells, and antibodies targeting CD47 for can...
The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis
The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis
Hepatocellular carcinoma (HCC) generally arises from a background of liver cirrhosis (LC). Patients with cirrhosis and sus...
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches....
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-smal...
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistan...
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several ge...
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor prognosis. Proteogenomic characterization and i...
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective th...
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for new...
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, ...
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis
Hepatocarcinogenesis is driven by necroinflammation or metabolic disorders, and the underlying mechanisms remain largely e...
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, d...
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. Co...
Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry
Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry
Identifying T cell epitopes on pancreatic ductal adenocarcinoma (PDAC) associated antigens or neoantigens has been a chall...